vs
EXACT SCIENCES CORP（EXAS）与Martin Marietta Materials（MLM）财务数据对比。点击上方公司名可切换其他公司
Martin Marietta Materials的季度营收约是EXACT SCIENCES CORP的1.3倍（$1.1B vs $878.4M），Martin Marietta Materials净利率更高（24.5% vs -9.8%，领先34.3%），EXACT SCIENCES CORP同比增速更快（23.1% vs -30.1%），Martin Marietta Materials自由现金流更多（$424.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -4.5%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
马丁·玛丽埃塔材料公司是美国大型集料及重型建筑材料供应商，业务覆盖美国26个州、加拿大及加勒比地区，主要为道路、人行道、地基等各类基建项目提供所需原材料。
EXAS vs MLM — 直观对比
营收规模更大
MLM
是对方的1.3倍
$878.4M
营收增速更快
EXAS
高出53.3%
-30.1%
净利率更高
MLM
高出34.3%
-9.8%
自由现金流更多
MLM
多$303.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
-4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.1B |
| 净利润 | $-86.0M | $279.0M |
| 毛利率 | 70.1% | 35.0% |
| 营业利润率 | -9.4% | 24.6% |
| 净利率 | -9.8% | 24.5% |
| 营收同比 | 23.1% | -30.1% |
| 净利润同比 | 90.1% | -4.8% |
| 每股收益（稀释后） | $-0.45 | $4.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASMLM
| Q4 25 | $878.4M | $1.1B | ||
| Q3 25 | $850.7M | $1.8B | ||
| Q2 25 | $811.1M | $1.8B | ||
| Q1 25 | $706.8M | $1.4B | ||
| Q4 24 | $713.4M | $1.6B | ||
| Q3 24 | $708.7M | $1.9B | ||
| Q2 24 | $699.3M | $1.8B | ||
| Q1 24 | $637.5M | $1.3B |
净利润EXASMLM
| Q4 25 | $-86.0M | $279.0M | ||
| Q3 25 | $-19.6M | $414.0M | ||
| Q2 25 | $-1.2M | $328.0M | ||
| Q1 25 | $-101.2M | $116.0M | ||
| Q4 24 | $-864.6M | $293.0M | ||
| Q3 24 | $-38.2M | $363.0M | ||
| Q2 24 | $-15.8M | $294.0M | ||
| Q1 24 | $-110.2M | $1.0B |
毛利率EXASMLM
| Q4 25 | 70.1% | 35.0% | ||
| Q3 25 | 68.6% | 33.1% | ||
| Q2 25 | 69.3% | 30.0% | ||
| Q1 25 | 70.8% | 24.8% | ||
| Q4 24 | 69.0% | 30.0% | ||
| Q3 24 | 69.4% | 31.7% | ||
| Q2 24 | 69.8% | 29.3% | ||
| Q1 24 | 70.0% | 21.7% |
营业利润率EXASMLM
| Q4 25 | -9.4% | 24.6% | ||
| Q3 25 | -3.0% | 27.4% | ||
| Q2 25 | -0.3% | 25.3% | ||
| Q1 25 | -13.6% | 14.3% | ||
| Q4 24 | -122.8% | 24.4% | ||
| Q3 24 | -5.6% | 25.9% | ||
| Q2 24 | -3.8% | 22.6% | ||
| Q1 24 | -16.7% | — |
净利率EXASMLM
| Q4 25 | -9.8% | 24.5% | ||
| Q3 25 | -2.3% | 22.4% | ||
| Q2 25 | -0.1% | 18.1% | ||
| Q1 25 | -14.3% | 8.6% | ||
| Q4 24 | -121.2% | 18.0% | ||
| Q3 24 | -5.4% | 19.2% | ||
| Q2 24 | -2.3% | 16.7% | ||
| Q1 24 | -17.3% | 83.5% |
每股收益（稀释后）EXASMLM
| Q4 25 | $-0.45 | $4.59 | ||
| Q3 25 | $-0.10 | $6.85 | ||
| Q2 25 | $-0.01 | $5.43 | ||
| Q1 25 | $-0.54 | $1.90 | ||
| Q4 24 | $-4.69 | $4.87 | ||
| Q3 24 | $-0.21 | $5.91 | ||
| Q2 24 | $-0.09 | $4.76 | ||
| Q1 24 | $-0.60 | $16.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $67.0M |
| 总债务越低越好 | — | $5.3B |
| 股东权益账面价值 | $2.4B | $10.0B |
| 总资产 | $5.9B | $18.7B |
| 负债/权益比越低杠杆越低 | — | 0.53× |
8季度趋势，按日历期对齐
现金及短期投资EXASMLM
| Q4 25 | $964.7M | $67.0M | ||
| Q3 25 | $1.0B | $57.0M | ||
| Q2 25 | $858.4M | $225.0M | ||
| Q1 25 | $786.2M | $101.0M | ||
| Q4 24 | $1.0B | $670.0M | ||
| Q3 24 | $1.0B | $52.0M | ||
| Q2 24 | $946.8M | $109.0M | ||
| Q1 24 | $652.1M | $2.6B |
总债务EXASMLM
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $5.5B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $5.4B | ||
| Q3 24 | — | $4.0B | ||
| Q2 24 | — | $4.3B | ||
| Q1 24 | — | $4.3B |
股东权益EXASMLM
| Q4 25 | $2.4B | $10.0B | ||
| Q3 25 | $2.5B | $9.7B | ||
| Q2 25 | $2.5B | $9.4B | ||
| Q1 25 | $2.4B | $9.1B | ||
| Q4 24 | $2.4B | $9.5B | ||
| Q3 24 | $3.2B | $9.2B | ||
| Q2 24 | $3.2B | $8.8B | ||
| Q1 24 | $3.1B | $8.9B |
总资产EXASMLM
| Q4 25 | $5.9B | $18.7B | ||
| Q3 25 | $5.9B | $18.7B | ||
| Q2 25 | $5.8B | $18.1B | ||
| Q1 25 | $5.7B | $17.7B | ||
| Q4 24 | $5.9B | $18.2B | ||
| Q3 24 | $6.7B | $16.5B | ||
| Q2 24 | $6.7B | $16.3B | ||
| Q1 24 | $6.4B | $16.2B |
负债/权益比EXASMLM
| Q4 25 | — | 0.53× | ||
| Q3 25 | — | 0.57× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | — | 0.60× | ||
| Q4 24 | — | 0.57× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $629.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $424.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 37.2% |
| 资本支出强度资本支出/营收 | 3.6% | 18.0% |
| 现金转化率经营现金流/净利润 | — | 2.25× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $978.0M |
8季度趋势，按日历期对齐
经营现金流EXASMLM
| Q4 25 | $151.7M | $629.0M | ||
| Q3 25 | $219.9M | $551.0M | ||
| Q2 25 | $89.0M | $387.0M | ||
| Q1 25 | $30.8M | $218.0M | ||
| Q4 24 | $47.1M | $686.0M | ||
| Q3 24 | $138.7M | $600.0M | ||
| Q2 24 | $107.1M | $1.0M | ||
| Q1 24 | $-82.3M | $172.0M |
自由现金流EXASMLM
| Q4 25 | $120.4M | $424.0M | ||
| Q3 25 | $190.0M | $361.0M | ||
| Q2 25 | $46.7M | $208.0M | ||
| Q1 25 | $-365.0K | $-15.0M | ||
| Q4 24 | $10.7M | $453.0M | ||
| Q3 24 | $112.6M | $317.0M | ||
| Q2 24 | $71.2M | $-138.0M | ||
| Q1 24 | $-120.0M | $-28.0M |
自由现金流率EXASMLM
| Q4 25 | 13.7% | 37.2% | ||
| Q3 25 | 22.3% | 19.6% | ||
| Q2 25 | 5.8% | 11.5% | ||
| Q1 25 | -0.1% | -1.1% | ||
| Q4 24 | 1.5% | 27.8% | ||
| Q3 24 | 15.9% | 16.8% | ||
| Q2 24 | 10.2% | -7.8% | ||
| Q1 24 | -18.8% | -2.2% |
资本支出强度EXASMLM
| Q4 25 | 3.6% | 18.0% | ||
| Q3 25 | 3.5% | 10.3% | ||
| Q2 25 | 5.2% | 9.9% | ||
| Q1 25 | 4.4% | 17.2% | ||
| Q4 24 | 5.1% | 14.3% | ||
| Q3 24 | 3.7% | 15.0% | ||
| Q2 24 | 5.1% | 7.9% | ||
| Q1 24 | 5.9% | 16.0% |
现金转化率EXASMLM
| Q4 25 | — | 2.25× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | — | 1.18× | ||
| Q1 25 | — | 1.88× | ||
| Q4 24 | — | 2.34× | ||
| Q3 24 | — | 1.65× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
MLM
| Building Materials Business East Group | $774.0M | 68% |
| Building Materials Business West Group | $233.0M | 20% |
| Services | $88.0M | 8% |
| Other | $45.0M | 4% |
